Trial reportGeroScience2026
rTMS modulates early AD progression via synergistic brain network reorganization and peripheral biomarker dynamics.
Trial report in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Repetitive transcranial magnetic stimulation (rTMS) improves cognition in Alzheimer's disease (AD), yet its biomarker and neuroplasticity effects remain unclear. Cognitive scale scores, plasma biomarker levels, and resting-state fMRI brain network in AD patients were analyzed before and after a 14-day 20 Hz rTMS intervention. The results demonstrated that rTMS intervention significantly improved cognitive performance (MMSE: Z = - 2.863, q = 0.017; MoCA: t = - 6.137, q < 0.001; RAVLT_I: t = - 3.436, q = 0.011) and reduced neuropsychiatric symptoms (NPI: Z = - 2.547, q = 0.037; HAMD: Z = - 3.472, q = 0.009). A 9.4% reduction in neurofilament light chain levels was demonstrated (Z = - 2.371, P = 0.018), with baseline p-Tau181 levels being inversely correlated to Aβ42 changes (R = - 0.428, P = 0.033). Enhanced global efficiency (GE: t = - 1.865, P = 0.081, r = 0.423) and increased connection density (CD: Z = - 1.823, P = 0.068, r = 0.442) were identified in neural networks. Notably, GE improvements positively correlated with elevated Aβ42/40 (R = 0.596, P = 0.025), while cognitive gains measured by the MoCA were significantly associated with network reorganization metrics (GE: R = 0.486, P = 0.048; CD: R = 0.514, P = 0.035). rTMS demonstrates potential in mitigating neurodegeneration by enhancing brain network integration and modulating Aβ metabolism. This effect was particularly pronounced in early-stage AD patients who exhibit preserved neural integrity. These findings advance therapeutic assessment frameworks and decode TMS neuromodulation mechanisms. The trial was prospectively registered (ChiCTR2400080657, ClinicalTrials.gov; 2024-02-04).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.